

WEST Search History

DATE: Monday, November 24, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side		result set	
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
L4	L3 and nucleoside	20	L4
L3	L2 and (tetrazol\$2 with ammonium)	23	L3
L2	L1 and tetrazole	780	L2
<i>DB=USPT; PLUR=YES; OP=ADJ</i>			
L1	((435/91.1)!.CCLS. (558/70)!.CCLS. (536/23.1 536/25.1 536/25.34 536/24.5)!.CCLS.)	10320	L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 12:01:28 ON 24 NOV 2003)

FILE 'REGISTRY' ENTERED AT 12:01:36 ON 24 NOV 2003

L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 0 S L1 SSS FULL

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 12:03:23 ON 24 NOV 2003

L4 1660 S INTERNUCLEOSIDE
L5 1660 S L4
L6 576 S L5 AND TETRAZOLE
L7 688 S L5 AND TETRAZOL?
L8 620 S L7 AND (AMMONIUM OR PYRIDINIUM)
L9 592 S L8 AND SUPPORT
L10 525 S L9 AND PYRIDINE
L11 6 S L10 AND METHYLPYRIDINE
L12 3 S L10 AND AMMONIUM TETRAZOLIDE

L12 ANSWER 1 OF 3 USPATFULL on STN
 ACCESSION NUMBER: 2000:88317 USPATFULL
 TITLE: Dinucleotide and oligonucleotide analogues
 INVENTOR(S): Baxter, Anthony David, Abingdon, United Kingdom
 Baylis, Eric Keith, Stockport, United Kingdom
 Collingwood, Stephen Paul, Crawley, United Kingdom
 Fairhurst, Robin Alec, Ashington, United Kingdom
 Taylor, Roger John, Southwater, United Kingdom
 PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6087490		20000711
	WO 9735869		19971002
APPLICATION INFO.:	US 1998-155198		19981008 (9)
	WO 1997-GB651		19971103
			19981008 PCT 371 date
			19981008 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-6158	19960323
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Riley, Jezia	
LEGAL REPRESENTATIVE:	Borovian, Joseph J.	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2923	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound which is a dinucleotide analogue of formula ##STR1## or a salt thereof, where B.sup.1 and B.sup.2 are each independently a monovalent nucleoside base radical,

R.sup.1 is hydrogen or Y.sup.1,

R.sup.2 and R.sup.3 are each independently hydrogen, halogen, hydroxy or --OY.sup.2,

R.sup.4 is hydrogen, halogen, hydroxy, --OY.sup.3 or R.sup.7,

R.sup.5 is hydrogen, halogen or R.sup.8,

R.sup.6 is hydrogen, Y.sup.4 or a phosphoramidyl group,

Z is a group of formula II, III or IV ##STR2## where R.sup.9 is hydrogen, halogen, hydroxy, --OY.sup.5 or R.sup.13, R.sup.10 is hydrogen, halogen or R.sup.14, R.sup.11 is hydroxy, R.sup.15 or --OR.sup.15 where R.sup.15 is a C.sub.1 to C.sub.10 aliphatic group, a C.sub.3 to C.sub.8 cycloaliphatic group, a C.sub.6 to C.sub.10 aromatic group or a C.sub.7 to C.sub.13 araliphatic group, and R.sup.12 is hydrogen, R.sup.12.sub.a or --OCOR.sup.12.sub.a where R.sup.12.sub.a is a C.sub.1 to C.sub.10 aliphatic group, a C.sub.3 to C.sub.8 cycloaliphatic group, a C.sub.6 to C.sub.10 aromatic group or a C.sub.7 to C.sub.13 araliphatic group, Y.sup.1, Y.sup.2, Y.sup.3, Y.sup.4 and Y.sup.5 are each independently a hydroxy-protecting group, and R.sup.7, R.sup.8, R.sup.13 and R.sup.14 are each independently a C.sub.1 to C.sub.10 aliphatic group, a C.sub.3 to C.sub.8 cycloaliphatic group, a C.sub.6 to C.sub.10 aromatic group or a C.sub.7 to C.sub.13 araliphatic group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 3 USPATFULL on STN
 ACCESSION NUMBER: 2000:64673 USPATFULL
 TITLE: Modified oligonucleotides
 INVENTOR(S): De Mesmaeker, Alain, Kanerkinden, Switzerland
 Waldner, Adrian, Allschwil, Switzerland
 Lebreton, Jacques, Marseilles, France
 Bevierre, Marc-Olivier, Fontainebleau, France
 Lesueur, Catherine, Chambray-les-Tours, France
 PATENT ASSIGNEE(S): Novartis Corporation, Summit, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6066447		20000523
	WO 9520597		19950803
APPLICATION INFO.:	US 1996-687456	19961112	(8)
	WO 1995-EP156	19950117	
		19961112	PCT 371 date
		19961112	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-1446	19940126
	GB 1994-12526	19940622
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Harschel, Ardin H.	
LEGAL REPRESENTATIVE:	Ferraro, Gregory D.	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2207	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Oligonucleotides of the formula: 5'(U).sub.n -3' in which U is an identical or different radical of a natural or a synthetic nucleoside and n is a number from 2 to 200 comprising at least one structural unit of two consecutive nucleosides wherein one of the nucleotides is substituted in the 2'-position or wherein the nucleotides are substituted differently in their 2'-position and wherein the backbone is modified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 3 USPATFULL on STN
 ACCESSION NUMBER: 2000:47356 USPATFULL
 TITLE: Process for the synthesis of oligomeric compounds
 INVENTOR(S): Ravikumar, Vasulinga T., Carlsbad, CA, United States
 PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6051699		20000418
	WO 9719092		19970529
APPLICATION INFO.:	US 1998-68275	19980506	(9)
	WO 1996-US18618	19961115	
		19980506	PCT 371 date
		19980506	PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-560540, filed on 17 Nov 1995, now patented, Pat. No. US 5705621		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wilson, James O.		
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP		
NUMBER OF CLAIMS:	62		

EXEMPLARY CLAIM:

1

LINE COUNT:

2479

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Synthetic processes are provided wherein oligomeric compounds are prepared having phosphodiester, phosphorothioate, and phosphorodithioate covalent linkages. Also provided are synthetic intermediates useful in the processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>